ODE III Director Botstein Retires From FDA; Raczkowski Will Head Office
Executive Summary
FDA's Office of Drug Evaluation III Deputy Director Victor Raczkowski, MD, is expected to become acting director at the beginning of the new year.
You may also be interested in...
Von Eschenbach May Speed Changes In “Strategic Direction” At FDA – Galson
FDA Acting Commissioner Andrew von Eschenbach could serve as a catalyst for policy initiatives at the agency, Center for Drug Evaluation & Research Director Steve Galson said Oct. 24
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011